528 related articles for article (PubMed ID: 22187171)
41. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Feng YX; Wang T; Deng YZ; Yang P; Li JJ; Guan DX; Yao F; Zhu YQ; Qin Y; Wang H; Li N; Wu MC; Wang HY; Wang XF; Cheng SQ; Xie D
Hepatology; 2011 Feb; 53(2):483-92. PubMed ID: 21274870
[TBL] [Abstract][Full Text] [Related]
42. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
43. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
45. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Ma D; Wang J; Liu L; Chen M; Wang Z
BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
[TBL] [Abstract][Full Text] [Related]
46. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
47. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
48. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
49. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
50. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
51. Neferine isolated from Nelumbo nucifera enhances anti-cancer activities in Hep3B cells: molecular mechanisms of cell cycle arrest, ER stress induced apoptosis and anti-angiogenic response.
Yoon JS; Kim HM; Yadunandam AK; Kim NH; Jung HA; Choi JS; Kim CY; Kim GD
Phytomedicine; 2013 Aug; 20(11):1013-22. PubMed ID: 23746959
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
53. Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways.
Cheng P; Dai W; Wang F; Lu J; Shen M; Chen K; Li J; Zhang Y; Wang C; Yang J; Zhu R; Zhang H; Zheng Y; Guo CY; Xu L
Biochem Biophys Res Commun; 2014 Jan; 443(4):1162-8. PubMed ID: 24361892
[TBL] [Abstract][Full Text] [Related]
54. Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Shih WL; Yu FL; Chang CD; Liao MH; Wu HY; Lin PY
Mol Carcinog; 2013 Oct; 52(10):800-12. PubMed ID: 22549898
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
Esposito V; Palescandolo E; Spugnini EP; Montesarchio V; De Luca A; Cardillo I; Cortese G; Baldi A; Chirianni A
Clin Cancer Res; 2006 Apr; 12(8):2634-9. PubMed ID: 16638877
[TBL] [Abstract][Full Text] [Related]
56. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
57. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
58. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of the Chinese traditional medicinal herb Celastrus orbiculatus Thunb on human hepatocellular carcinoma in an orthothopic fluorescent nude mouse model.
Wang M; Zhang X; Xiong X; Yang Z; Sun Y; Yang Z; Hoffman RM; Liu Y
Anticancer Res; 2012 Apr; 32(4):1213-20. PubMed ID: 22493351
[TBL] [Abstract][Full Text] [Related]
60. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.
Chen G; Wang Y; Zhou M; Shi H; Yu Z; Zhu Y; Yu F
Oncol Rep; 2010 Feb; 23(2):563-70. PubMed ID: 20043122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]